Hadasit, the Hadassah Medical Organization’s technology transfer company, and Israel’s BioLineRx are to develop a treatment BL-1210 for non-alcoholic steatohepatitis (NASH) or fatty liver disease.  It modulates the immune system to reduce scarring that leads to cirrhosis.  There is currently no FDA approved treatments.

http://www.hadassah.org/news-stories/NASH-liver-disease.html